指南与共识消化道肿瘤放疗

肝细胞癌放射治疗:综合更新与实用建议

Radiotherapy for Hepatocellular Carcinoma: A comprehensive update with practical recommendations.
指南 / 共识 · Pract Radiat Oncol · 2026-10-26

本文综述了外照射放疗(EBRT)在肝细胞癌(HCC)中的实践应用,综合共识指南、前瞻性随机试验和当代系列研究,涉及患者选择、治疗实施、粒子治疗、与其他局部治疗比较、联合系统治疗、高危场景管理、桥接移植及治疗后监测。成熟前瞻性证据显示EBRT局部控制不劣于或优于标准化局部治疗且毒性可接受,主要指南已将其纳入特定临床场景的选项。

要点

  • EBRT局部控制不劣于或优于标准化局部治疗,毒性可接受。
  • 运动管理、图像引导和自适应计划等技术进步扩大了高危场景的安全应用。
  • EBRT是有效的桥接移植治疗,主要指南已 endorse 其在特定场景的应用。

核心结论

  • EBRT提供 excellent 局部控制且毒性可接受,主要指南已将其纳入特定场景的选项。
  • 随着影像、运动管理、自适应策略和功能肝脏评估的进步,EBRT可安全地 tailored 于肝脏储备受损、大血管侵犯或移植路径的患者。

研究设计与样本

  • 本综述综合了当前共识指南、前瞻性随机试验和评估EBRT用于HCC的关键当代系列研究,并借鉴了更新至近期研究的既往系统综述。

主要发现

  • 成熟前瞻性证据,包括与化疗栓塞、热消融和系统治疗的随机比较,显示EBRT局部控制等于或优于标准化局部治疗且毒性可接受。
  • 运动管理、图像引导、功能肝脏评估和自适应计划的进步扩大了EBRT在高危场景(如大血管侵犯、肝功能差和再照射)的安全应用。
  • EBRT是有效的桥接治疗。

临床怎么用

  • 放射肿瘤科医生可依据本综述为患者选择、治疗计划和在当代局部及系统治疗中定位EBRT提供实用基础。

局限性

  • 未来研究应细化患者选择并优化EBRT与其他肝脏导向及系统治疗的组合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Management of hepatocellular carcinoma (HCC) is evolving rapidly and decisions regarding locoregional therapy are complex. External beam radiation therapy (EBRT) is a highly effective and safe intervention with an expanding role in HCC, and major guidelines (BCLC 2026, EASL, AASLD, NCCN, ASTRO) now endorse it across defined clinical settings. However, guidelines largely treat EBRT as a single modality, whereas in practice it encompasses multiple delivery techniques and nuanced technical decisions that directly influence safety and efficacy. This review provides radiation oncologists with a practical foundation for selecting patients, planning treatment, and positioning EBRT among contemporary locoregional and systemic therapies. METHODS AND MATERIALS: We synthesized current consensus guidelines, prospective randomized trials, and key contemporary series evaluating EBRT for HCC, drawing on prior systematic reviews updated to include recent studies. We address liver function assessment and patient selection, practical aspects of treatment delivery (motion management, image guidance, target definition, and adaptive planning), particle therapy, comparative evidence against other locoregional therapies, combinations with systemic therapy, management of high-risk scenarios, bridging to transplant, and post-treatment surveillance. RESULTS: Mature prospective evidence, including randomized comparisons against chemoembolization, thermal ablation, and systemic therapy, demonstrates that EBRT achieves local control equal or superior to standard locoregional therapies with acceptable toxicity. Advances in motion management, image guidance, functional liver assessment, and adaptive planning have expanded the safe application to high-risk scenarios, such as macrovascular invasion, poor liver function, and re-irradiation, and EBRT is an effective bridging therapy. CONCLUSIONS: EBRT delivers excellent local control with acceptable toxicity and is now endorsed by major guidelines as an option in selected settings. As imaging, motion management, adaptive strategies, and functional liver assessment continue to evolve, EBRT can be tailored safely to patients with compromised liver reserve, macrovascular invasion, or transplant pathways. Future studies should refine patient selection and optimize combinations of EBRT with other liver-directed and systemic therapies.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yanagihara, Dawson, Makishima, et al. Radiotherapy for Hepatocellular Carcinoma: A comprehensive update with practical recommendations. Pract Radiat Oncol. 2026. PMID: 42933729. doi:10.1016/j.prro.2026.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。